Related Experiment Video
Updated: Oct 8, 2026

Analysis of the c-KIT Ligand Promoter Using Chromatin Immunoprecipitation
Published on: June 27, 2017
Transcriptional activation of mouse sst2 somatostatin receptor promoter by transforming growth factor-beta.
E Puente1, N Saint-Laurent, J Torrisani
1INSERM U 531, Institut Louis Bugnard, 31403, Toulouse, France.
Abstract:
The sst2 somatostatin receptor is an inhibitory G protein-coupled receptor, which exhibits anti-tumor properties. Expression of sst2 is lost in most human pancreatic cancers. We have cloned 2090 base pairs corresponding to the genomic DNA region upstream of the mouse sst2 (msst2) translation initiation codon (ATG). Deletion reporter analyses in mouse pituitary AtT-20 and human pancreatic cancer PANC-1, BxPC-3, and Capan-1 cells identify a region from nucleotide -260 to the ATG codon (325 base pairs) showing maximal activity, and a region between nucleotides -2025 and -260 likely to comprise silencer or transcriptional suppressor elements. In PANC-1 and AtT-20 cells, transforming growth factor (TGF)-beta up-regulates msst2 transcription. Transactivation is mediated by Smad4 and Smad3. The cis-acting region responsible for such regulation is comprised between nucleotides -1115 and -972 and includes Sp1 and CAGA-box sequences. Expression of Smad4 in Smad4-deficient Capan-1 and BxPC-3 cells restores TGF-beta-dependent and -independent msst2 transactivation. Expression of Smad4 in BxPC-3 cells reestablishes both endogenous sst2 expression and somatostatin-mediated inhibition of cell growth. These findings demonstrate that msst2 is a new target gene for TGF-beta transcription regulation and underlie the possibility that loss of Smad4 contributes to the lack of sst2 expression in human pancreatic cancer, which in turn may contribute to a stimulation of tumor growth.
Insights
The somatostatin receptor 2 (sst2) gene, crucial for inhibiting tumor growth, is often lost in pancreatic cancers. This study identifies key regulatory elements and shows that TGF-beta, via Smad4, can restore sst2 expression, offering potential therapeutic insights.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- The somatostatin receptor 2 (sst2) is an inhibitory G protein-coupled receptor with anti-tumor properties.
- sst2 expression is frequently lost in human pancreatic cancers, suggesting a role in tumor progression.
Purpose of the Study:
- To identify regulatory elements controlling mouse sst2 (msst2) gene transcription.
- To investigate the role of transforming growth factor-beta (TGF-beta) and Smad proteins in msst2 regulation.
- To explore the potential link between Smad4 deficiency, sst2 loss, and pancreatic cancer growth.
Main Methods:
- Cloning of the upstream genomic DNA region of msst2.
- Deletion reporter analyses in various cell lines (AtT-20, PANC-1, BxPC-3, Capan-1).
- Investigating TGF-beta-mediated transactivation using Smad3 and Smad4, and analyzing cis-acting elements (Sp1, CAGA-box).
Main Results:
- A 325-base pair region (-260 to ATG) showed maximal promoter activity; a silencer region was identified between -2025 and -260.
- TGF-beta up-regulates msst2 transcription in PANC-1 and AtT-20 cells, mediated by Smad4 and Smad3.
- Expression of Smad4 restored TGF-beta-dependent/independent msst2 transactivation in deficient cells and reestablished sst2 expression and somatostatin-mediated growth inhibition in BxPC-3 cells.
Conclusions:
- msst2 is a novel target gene for TGF-beta transcriptional regulation.
- Loss of Smad4 may contribute to the lack of sst2 expression in pancreatic cancer, potentially promoting tumor growth.
More Related Videos
Related Concept Videos
TGF - β Signaling Pathway
Master Transcription Regulators
Hedgehog Signaling Pathway
Co-activators and Co-repressors
General Transcription Factors
Transcription Factors

